The site will be a cell collection center, a shipping warehouse, and a training and research facility. The company aims to work with the University of Nevada, Reno's science programs.

StemExpress' northern Nevada facility. Image courtesy of StemExpress.

StemExpress currently has seven locations in California, Massachusetts, Maryland, Philadelphia, and North Carolina. The company supports medical research, clinical trials, and commercialization of disease-specific treatment, cell and gene therapies, and precision medicine.

2nd-gen stem cell-derived CAR gene therapy is more durable, effective against HIV
A novel second-generation chimeric antigen receptor (CAR)-based approach targeting HIV infection using the genetic modification of hematopoietic stem...

Cancer anti-inflammatory drug has potential to treat severe COVID-19
A new study provides evidence that an inexpensive clinical-grade inhibitor that's already approved to treat cancer, called topotecan, can be used to treat...

FDA approves 1st cell-based gene therapy for multiple myeloma
On March 27 the U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma), the first cell-based gene therapy for treating adult...

Scientists develop ultraspecific CAR T cells that kill only cancer cells
Scientists have devised a two-step engineering circuit that precisely targets solid tumors with chimeric antigen receptor (CAR) T cells. The engineering...

AI uncovers the genome's hidden regulatory code
A neural network trained on high-resolution maps of protein-DNA interactions can uncover how these sequences are organized to regulate genes, revealing...